ECOG Performance Status ≥ 2 as a prognostic factor in patients with advanced Non Small Cell Lung Cancer treated with Immune Checkpoint Inhibitors– A systematic review and meta-analysis of real world data

Immune-checkpoint inhibitors (ICIs) represented by programmed death receptor inhibitors (PD-1), programmed death receptor ligand inhibitors (PD-L1) and cytotoxic-T-lymphocytes antigen 4 inhibitors (CTLA-4), drastically changed the management of several neoplastic diseases, including metastatic non-small-cell lung cancer (NSCLC), melanoma, and metastatic renal cell carcinoma (RCC).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research